Rubella Antibody, IgG
Rubella (German measles) is a member of the Togaviridae family, a single stranded enveloped RNA virus. The disease is highly contagious and usually transmitted through respiratory secretions but also through urine, feces and skin lesions. Primary infections are generally mild and self-limited, with symptoms such as a mild rash (rubella means "little red"), low-grade fever, and lymphadenopathy. In contrast, primary infections during the first trimester of pregnancy can pass transplacentally to the fetus and can lead to fetal death or congenital rubella syndrome (CRS). It is estimated between 10% to 20% of newborn infants infected in utero fail to survive past the first 10 months of life. Babies born with CRS typically exhibit low birth weight, deafness, eye disease, mental retardation, and cardiac abnormalities. Immunity usually develops in all cases of congenital rubella; however, almost one third usually lose the antibody in late childhood. Before vaccination began in 1969, German measles was mainly a disease of young children; however today it is mainly seen in young unvaccinated adults. In 1964-65 there was a pandemic in the U.S. with an estimated 12.5 million cases; in 2009 there were three cases reported to the CDC.
Children that are known to have had congenital rubella should be screened in late childhood and vaccinated if needed. A primary infection induces an IgM and an IgG response. Within 4 to 6 months, IgM levels usually become undetectable or very low although they can persist for up to a year. IgG levels decrease to low levels but last indefinitely, and this confers lifelong immunity in many cases. A titer of < 1:8 indicates susceptibility and the need for immunization to prevent infection during pregnancy. A titer of > 1:32 indicates immunity. A second infection exhibits a rising IgG antibody without significant levels of IgM. Only one serological type of rubella virus is found in the population.
The hemagglutination inhibition (HAI) antibody test is the most frequently used screening method for the presence of rubella antibodies. HAI does not distinguish between IgG or IgM, but detects both. Latex procedures can provide more rapid and convenient alternatives; however, if a quantitative level is required, EIA and FIA are available. Since the introduction of the rubella vaccine in the late 1960s the incidence of CRS has dropped dramatically; however, outbreaks of rubella still occur and pose a potential risk to women of childbearing age. Immunity from the vaccine is shown to persist for more than 16 years. An antibody level of 10 IU/mL is thought to be protective.
- Diagnosis of rubella infection
- Prenatal screening for congenital rubella syndrome
- Aid in the assessment of immune status of rubella
Positive in:
- Patients currently infected with rubella virus
- Patients with past history of rubella infection
- Patient vaccinated with rubella vaccine
<5 IU/mL - Negative, not immune
5-9 IU/mL – Equivocal
>10 IU/mL – Positive (immune), indicative of current, or previous exposure or immunization
Direct chemiluminometric immunoassay, chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST), cerebrospinal fluid collected in a sterile cntainer.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 60 days
CSF: Ambient unacceptable.
- J Med Virol. 1992 Mar;36(3):188-92. [PMID: 1314284]
- J Clin Virol. 1999 Oct;14(2):107-18. [PMID: 10588453]
- Epidemiol Infect. 1990 Jun;104(3):489-97. [PMID: 2347387]
- J Virol Methods. 1991 Feb-Mar;31(2-3):219-28. [PMID: 1864907]
- J Virol Methods. 2005 Dec;130(1-2):59-65. [PMID: 16026863]
- Pathol Biol (Paris). 1992 Sep;40(7):706-10. [PMID: 1480405]